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SUMMARY – Th e objective of this study was to determine diff erential expression of TFF1, TFF2 
and TFF3 genes and proteins in breast tumor subtypes. In addition, we investigated the correlation 
between TFF genes within tumor subgroups, and TFF genes with clinical and pathologic character-
istics of the tumor. Study group included 122 patients with surgically removed breast tumors. Samples 
were investigated using qRT-PCR and immunohistochemistry. TFF1 and TFF3 genes and proteins 
were expressed in breast tumors, while the levels of TFF2 gene and protein expression were very low 
or undetectable. TFF1 was signifi cantly more expressed in benign tumors, while TFF3 was more ex-
pressed in malignant tumors. Gene and protein expression of both TFF1 and TFF3 was greater in 
lymph node-negative tumors, hormone positive tumors, tumors with moderate levels of Ki67 expres-
sion, and in grade II tumors. A strong positive correlation was found between TFF1 and TFF3 genes, 
and the expression of both negatively correlated with Ki67 and the level of tumor histologic diff eren-
tiation. Our results suggest that TFF1 and TFF3, but not TFF2, may have a role in breast tumor 
pathogenesis and could be used in the assessment of tumor diff erentiation and malignancy.
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Introduction
Breast cancer is the most common form of cancer 
aff ecting women worldwide, and is a global health, 
economic and social problem1. Malignant breast tu-
mors are a highly heterogeneous tumor group and are 
therefore diffi  cult to classify into uniform subgroups 
that could be used to assess malignancy of the tumor, 
choose appropriate treatment, and thus ensure long-
term survival of patients2. According to St. Gallen 
consensus, which is based on estrogen receptor (ER), 
progesterone receptor (PR) and human epidermal 
growth factor receptor (HER2) expression, tumors are 
divided into four subgroups: Luminal A (Lum A), Lu-
minal B (Lum B), HER2 positive (HER2 pos) and 
triple negative (triple neg)3. Th is consensus can apply 
to all types of breast tumors regardless of their histo-
logic type and is of substantial clinical signifi cance be-
cause it helps assess tumor malignancy and select ap-
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propriate treatment4. However, breast tumors still ex-
hibit substantial histologic and clinical heterogeneous-
ness. Th erefore, new biomarkers are needed to improve 
diagnosis, assess progression of the disease and choose 
appropriate tumor therapy to ease treatment and pro-
long patient survival5.
Trefoil factor family (TFF) proteins are small se-
cretory proteins expressed mainly in the gastrointesti-
nal tract, but are also found in many other human tis-
sues. Th e trefoil factor family consists of three mem-
bers (TFF1, TFF2 and TFF3) expressed in diff erent 
human tissues6,7. TFF proteins participate in numer-
ous physiologic and pathologic processes through dif-
ferent mechanisms. Th eir versatile functions are im-
portant in mucosal restitution and repair processes, cell 
adhesion, motility, apoptosis, and angiogenesis8-10. 
Th ey are also found in diff erent tissues during embry-
onic development11. Apart from healthy tissues, TFF 
proteins are expressed in various pathologically 
changed tissues, such as infl amed gut in the infl amma-
tory bowel disease and malignant tumors, including 
breast cancer12. Th ere is a controversy regarding the 
impact of TFF1 protein on the malignant properties of 
breast cancer. Some studies indicate that it enhances 
breast cancer development13-16, whereas others propose 
a tumor-suppressive role17-20. At fi rst, TFF2 protein 
was not found in the epithelium of either normal or 
pathologically changed breasts21. Later experiments 
have revealed that TFF2 protein is expressed in breast 
cancer cell line, both in normal breast cells and in 
breast tumor cells, and has a motogenic eff ect on breast 
cancer cells in cell culture; however, it is secreted in 
very small amounts compared to TFF1 and TFF3 pro-
teins22. According to experiments on breast cancer cell 
lines, TFF2 protein is considered a negative prognostic 
biomarker23-25. Past studies of TFF3 protein have indi-
cated that it promotes invasiveness, prevents apoptosis 
of tumor cells, and stimulates neoangiogenesis in tu-
mor tissue, allowing tumor progression and promoting 
its malignancy. TFF3 protein has been therefore cate-
gorized as a biomarker indicating poor prognosis, even 
though it is expressed more strongly in hormone re-
ceptor-positive tumors, which have better progno-
sis9,26-29.
Th e objective of this study was to determine dif-
ferential expression of TFF genes and TFF proteins in 
various breast tumor subtypes. Additionally, we as-
sessed correlation between TFF genes within the tu-
mor subgroups and their correlation with the clinical 
and pathologic characteristics of the tumor in order to 
determine their value as potential biomarkers.
Our results suggested that TFF1 and TFF3, unlike 
TFF2, may have a role in breast tumor pathogenesis 
and could be used in the assessment of tumor malig-
nancy only in particular breast tumor subgroups. In-
creased expression of TFF1 could be used as a poten-
tial biomarker indicating good prognosis, whereas 
TFF3 could be helpful in tumor status assessment.
Patients and Methods
Study population
Th e study included 122 female patients that under-
went surgery at the Department of Surgery, Osijek 
University Hospital Centre for obvious breast tumor. 
Th e study lasted for 30 months (2014-2016). Th e test 
group comprised of 91 surgical patients with malig-
nant breast tumors and 31 patients with fi broadeno-
mas (benign breast tumors) surgically removed30. On 
analyzing the data obtained, we subdivided the malig-
nant group depending on hormone receptor status 
(2011 St. Gallen consensus)4, histologic grade (Not-
tingham Grading System)31, aff ectio n of lymph nodes 
by metastases, and levels of expression of the Ki67 pro-
liferation marker.
Gene analysis
Tumor samples for gene expression analysis were 
obtained during surgical procedures and were immedi-
ately stored in the RNAlater® total RNA integrity 
preservation solution (Applied Biosystems, USA). Th e 
collected samples were kept at room temperature for 
one hour and afterwards stored at -80 °C until total 
RNA isolation process.
Tissue samples were homogenized with liquid ni-
trogen. Total RNA isolation was performed using the 
TRI Reagent (Life Technologies, USA) according to 
the manufacturer’s protocol. Total RNA was diluted 
with 30 μL of DEPC-treated water (Santa Cruz, 
USA) and stored at -80 °C. Amplifi cation Grade DN-
ase I (Sigma-Aldrich, USA) commercial kit was used 
to remove DNA molecules from RNA samples, fol-
lowing the manufacturer’s protocol. NanoPhotome-
ter® P-Class P330-30 micro volume spectrophotom-
eter (Implen, Germany) was used to determine RNA 
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concentration and sample purity. Isolated RNA was 
transcribed into cDNA using reverse transcriptase 
from the PrimeScriptTM RT reagent Kit (Perfect 
Real Time, Takara, USA) commercial kit. Th e reaction 
was performed in a CFX96 device (Bio Rad, USA) for 
120 minutes at 37 °C, followed by 5 seconds at 85 °C. 
Th e reaction mixture was then cooled to 4 °C.
Nucleotide sequences for the primers were chosen 
using the primer designing program available on the 
website http://eu.idtdna.com/site and literature32. Op-
timal reaction c onditions in which an effi  ciency rang-
ing from 95% to 100% was achieved were determined 
for each individual gene primer pair. Each sample was 
processed in duplicate. qRT-PCR reactions were per-
formed in the following conditions: enzyme activation 
at 95 °C for 30 seconds followed by 40 cycles of dena-
turation at 95 °C for 5 seconds, primer annealing at 
55-60 °C for 5 seconds (40 cycles) and 10 seconds at 
55-63 °C, with the fi nal disassociation step. qRT-PCR 
was performed on a Real Time PCR System Bio Rad 
CFX96 device. Actin beta (ACTB) gene expression 
was used to normalize gene expression33. Primer se-
quences and annealing temperature used for qRT-
PCR analysis are presented in Table 1.
Protein analysis
Protein expression was accompanied by immuno-
histochemical sample analysis. Th e patient cohort 
comprised of 75 surgical patients with breast tumors 
removed, 15 (20%) of which were fi broadenoma sam-
ples (benign tumors) and 60 (80%) malignant tumor 
samples. All samples were collected at the Department 
of Pathology and Forensic Medicine, Osijek Univer-
sity Hospital Centre. All samples were subjected to an 
initial histopathologic analysis and were histopatho-
logically reconfi rmed by an independent pathologist. 
Formalin-fi xed and paraffi  n-embedded sections of 
breast tumor tissue were deparaffi  nized and rehydrat-
ed. Endogenous peroxidase blocking using 0.3% hy-
drogen peroxide (15 minutes) was performed on the 
sections, followed by antigen retrieval in citrate buff er 
(pH=6.0) by heating in a microwave oven for 5 min-
utes. Th e primary antibody was applied to the slides, 
and incubated at 4 °C overnight. Primary antibodies 
used in this study were anti-TFF1 (Anti-Estrogen In-
ducible Protein pS2 antibody ab92377, Abcam, USA), 
anti-TFF2 (Anti-Spasmolytic Polypeptide antibody 
ab131147, Abcam, USA) and anti-TFF3 (purifi ed 
polyclonal rabbit anti-TFF3 antibody, proprietary, 
self-made)34. Negative controls were incubated with 
phosphate-buff ered saline (PBS, pH=7.4) instead of 
primary antibody. Human stomach tissue was used as 
positive control for TFF1 and TFF2 proteins, and hu-
man colon tissue was used as positive control for TFF3 
protein. Following primary antibody incubation, the 
sections were washed in PBS with Tween (0.05%) 
(Sigma Aldrich, USA) four times. Th is was followed 
by application of secondary antibody (affi  nity purifi ed, 
biotinylated goat anti-rabbit IgG, Vector Laboratories, 
USA), left at room temperature for 120 minutes. Th is 
procedure was followed by four more washes in PBS 
with 0.05% Tween, after which the slides were incu-
bated with streptavidin conjugated to horseradish per-
oxidase (Streptavidin-HRP, Vector Laboratories, 
USA) at room temperature for 45 minutes. After four 
more washes in PBS with Tween, 3.3’-diaminobenzi-
dine solution was applied (DAB Peroxidase (HRP) 
Substrate Kit, Vector Laboratories, USA). After four 
Table 1. Primer sequences and primer annealing temperature used on qRT-PCR analysis













TFF1 = trefoil factor family 1 gene; TFF2 = trefoil factor family 2 gene; TFF3 = trefoil factor family 3 gene; 
ACTB = actin beta gene
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washes in PBS with Tween, the slides were counter-
stained with hematoxylin and dehydrated in appropri-
ate solutions. Slides were mounted using Canada bal-
sam and covered with coverslips. Th e analysis was per-
formed at the Histology Laboratory, Faculty of Medi-
cine in Osijek.
Th e slides thus obtained were analyzed by two in-
dependent histologists. Th ey were photographed using 
an Olympus® C-5050 digital camera connected to an 
Olympus® BX-50 microscope and QuickPHOTO 
Pro software. Th e histomorphological analysis deter-
mined the existence, proportion and signal strength of 
TFF protein expression in individual samples using 
the Modifi ed Quick Score (Q) method of immunohis-
tochemical staining35,36. Modifi ed Quick Score meth-
od is presented in Table 2.
used for correlation assessment. All p-values were two-
sided. Materiality level was set to α=0.05. MedCalc 
statistical software (version 16.2.0, MedCalc Software 
bvba, Ostend, Belgium) was used on statistical analy-
sis. GraphPad Prism software (version 6, GraphPad 
Software, Inc., USA) was used to make the fi gures.
Compliance with ethical standards
An informed consent was obtained from all pa-
tients included in the study. Th e study obtained ap-
proval from local ethics committees, the Ethics Com-
mittee of the Osijek University Hospital Centre (25-
1:15401-3/2013) and Ethics Committee of the Fac-
ulty of Medicine, Josip Juraj Strossmayer University in 
Osijek (2158-61-07-15-125), and was performed in 
accordance with the ethical standards laid down in the 
1964 Declaration of Helsinki.
Results
Patient population and clinicopathologic characteristics
Th e study included 122 patients, age median 62 
years (interquartile range 45-74 years), ranging from 
18 to 88 years of age. Th irty-one (25%) patients had 
benign tumor (fi broadenomas) and 91 (75%) had ma-
lignant tumor. Th e subjects with malignant tumors 
were considerably older, age median 68 years (inter-
quartile range 57-76 years; p<0.001). Body mass index 
(BMI) was considerably higher in the group of sub-
jects with malignant tumors as compared to subjects 
with benign tumors (fi broadenoma). Within the ma-
lignant group, 78 (85.7%) tumors were hormone re-
ceptor-positive and 13 (14.3%) tumors were hormone 
receptor-negative. According to the St. Gallen con-
sensus, there were 20 (22%) Lum A, 58 (63.7%) Lum 
B, 4 (4.4%) Her 2 positive and 9 (9.9%) triple negative 
tumors (Table 3). Within the malignant group, 50 
(54.9%) subjects had metastases in lymph nodes, 
whereas 41 (45.1%) subjects did not have metastases 
in lymph nodes. Histologic diff erentiation grade, Ki67 
level of expression and other pathologic characteristics 
of the samples are presented in Table 3.
TFF gene expression
Th e expression of TFF1 mRNA was substantially 
higher in the benign tumor group consisting of sub-
jects with fi broadenomas compared to subjects from 
Table 2. Modifi ed Quick Score (Q) method for 
immunohistochemistry protein expression analysis
Proportion score (A) Intensity score (B)
No signal <1% - 0 No signal - 0
Proportion of positive 
cells 1%-10% - 1
Weak signal - 1
Proportion of positive 
cells 11%-33% - 2 
Moderately strong signal - 2
Proportion of positive 
cells 34%-66% - 3
Strong signal - 3
Proportion of positive 
cells 67%-100% - 4
Q = A + B, where Q marks the Quick Score total result; A = pro-
portion score; B = intensity score; minimum Q score was 0 and 
maximum was 7.
Statistical methods
Sample size was defi ned based on preliminary re-
search results. A minimum sample size of 22 subjects 
per group or 44 subjects in 2 groups was required to 
detect a 0.4 eff ect with α=0.05 and test strength of 0.8. 
Category data was presented in absolute and relative 
frequencies. Numerical data were described by median 
and interquartile range limits. Th e χ2-test and, where 
necessary, Fisher exact test were used to test category 
variable diff erences. Th e Shapiro-Wilk test was used to 
test the normality of numeric variable distribution. Th e 
Mann-Whitney U test was used to test numeric vari-
able diff erences due to deviations from normal distri-
bution. Spearman’s rank correlation coeffi  cient was 
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the malignant group (p=0.048) (Fig. 1, panel A). Our 
study revealed a very low level of TFF2 mRNA ex-
pression in benign breast tumors and extremely low 
TFF2 expression in malignant breast tumors, thus 
TFF2 was not expressed (Fig. 7, panel A). TFF3 
mRNA expression was higher in the malignant tumor 
group, but statistically signifi cant diff erence was not 
noted (p=0.44) (Fig. 1, panel A). Within the malig-
nant group, both TFF1 and TFF3 were expressed 
more strongly in the hormone receptor-positive tumor 
group (Fig. 1, panel B), but only TFF3 exhibited a sta-
tistically signifi cant mRNA expression diff erence 
(p=0.004) (Fig. 1, panel B). Comparing the results be-
tween the groups defi ned according to St. Gallen con-
sensus, we found that TFF1 was expressed most 
strongly in Lum A subgroup and TFF3 was most 
T able 3. Patient and clinicopathologic characteristics
Patient characteristics
Benign group Malignant group Total p value















Menopause 5/31 (16.1%) 80/91 (87.9%) 85/122(69.7%) <0.0011**
Pathologic characteristics
Tumor type (St. Gallen consensus)
Malignant tumors Luminal A 20/91 (22%)
Luminal B 58/91 (63.7%)
Her 2 positive 4/91 (4.40%)
Triple negative 9/91 (9.90%)
Metastasis
Malignant tumors Lymph node negative 50/91 (54.9%)
Lymph node positive 41/91 (45.1%)
Tumor diff erentiation





diff erentiated tumors 
(grade II)
42 (46.2%)














n = number of patients; BMI = body mass index; *Mann Whitney U test, data are presented as median and 
interquartile range limits, p<0.05 was considered signifi cant; **Fisher exact test, p<0.05 was considered 
 signifi cant
Maja Tolušić Levak et al. Diff erential expression of TFFs in breast tumors
Acta Clin Croat, Vol. 57, No. 2, 2018 269
Fig. 1. Distribution of TFF1 and TFF3 mRNA expression in benign (B) and malignant (M) breast tumors (panel 
A); hormone receptor-positive (HR+) and hormone receptor-negative (HR-) malignant breast tumors (panel B); 
malignant tumor subgroups according to St. Gallen consensus (panel C); and breast tumors with metastases in lymph 
nodes (Pos) and without lymph node metastases (Neg) (panel D). Th e test group comprised of 91 malignant and 31 
benign (fi broadenomas) surgically removed human breast tumors. Relative mRNA expression was measured by qRT- 
PCR; all measured genes were normalized to expression of Actin beta (ACTB) gene. Data are presented as median and 
interquartile range limits, horizontal bars represent the median, boxes indicate the range of the third and second 
quartiles, and whiskers represent extreme values of all data. Expression of TFF1 was signifi cantly higher in benign 
tumors (Mann Whitney U test, p=0.048) and lymph node negative tumors (Mann Whitney U test, p=0.043), while 
the levels of TFF3 mRNA were signifi cantly higher in HR+ tumors (Mann Whitney U test, p=0.004) and Lum B 
tumors (Kruskal Walis test, p=0.005); *p<0.05 was considered signifi cant.
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strongly expressed in Lum B subgroup (p=0.17 and 
p=0.005, respectively) (Fig. 1, panel C).  TFF1 and 
TFF3 expression was higher in subjects with tumors 
that did not have metastases in lymph nodes (Fig. 1, 
panel D).
Strong positive correlation between TFF1 and 
TFF3 was recorded within the malignant tumor group 
(p<0.001; ρ=0.731) (Fig. 2, panel A) and it was even 
more prominent in the hormone receptor-positive 
malignant tumor subgroup (p<0.001; ρ=0.747) (Fig. 2, 
panel B).
Comparing the results between the malignant sub-
groups defi ned according to tumor histologic diff eren-
tiation grade, a signifi cant diff erence in the expression 
of TFF1 and TFF3 mRNA was observed. Th e moder-
ately diff erentiated tumor subgroup (grade II) had the 
highest TFF1 and TFF3 expression, while the poorly 
diff erentiated tumor group (grade III) had the lowest 
expression (p=0.008 and p=0.001, respectively) (Fig. 3, 
panel A). Strong positive correlation between TFF1 
and TFF3 was found in all three subgroups defi ned by 
tumor histologic diff erentiation grade, but was stron-
gest in well-diff erentiated tumors (grade I) (p<0.001; 
ρ=0.770) (Fig. 2, panel C).
When classifying malignant tumors according to 
the level of Ki67 expression, the highest expression of 
TFF1 and TFF3 was measured in the group of tumors 
with moderately high expression of Ki-67 (Fig. 3, pan-
el B). Even though the results did not yield a statisti-
cally signifi cant diff erence in mRNA expression be-
tween the subgroups, a mild negative correlation was 
observed for Ki67 with TFF1 and TFF3 in the malig-
nant group. As Ki67 expression increased, the expres-
sion of TFF1 (p=0.028; ρ=-0.248) (Fig. 4, panel A) 
and TFF3 (p=0.011; ρ=-0.285) (Fig. 4, panel B) de-
creased signifi cantly. Th e most prominent correlation 
was recorded between Ki67 and TFF3 in the hormone 
receptor-negative tumor subgroup (p=0.03; ρ=-0.629) 
(Fig. 4, panel C).

Fig. 2. Correlation between TFF1 and TFF3 mRNA 
expression within the malignant group (panel A); 
hormone receptor-positive (HR+) and hormone 
receptor-negative (HR-) malignant tumor subgroups 
(panel B); and malignant tumor subgroups defi ned by 
histologic diff erentiation grade: I (good), II (moderate) 
and III (poor) (panel C). Strong positive correlation was 
observed between TFF1 and TFF3 in malignant tumor 
group (Spearman rank correlation; p<0.001, ρ=0.731), 
in HR+ tumor subgroup (Spearman rank correlation; 
p<0.001, ρ=0.747) and in tumor subgroups with good 
histologic diff erentiation (Spearman rank correlation; 
p<0.001, ρ=770); *p<0.05 was considered signifi cant.
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TFF protein expression
Th e immunohistochemical signal of TFF1 and 
TFF3 proteins was visible in the cytoplasm of tumor 
cells and there was no evidence of nuclear immunore-
action (Fig. 5). TFF1 protein expression was higher in 
the benign tumor group (p<0.001) (Fig. 6, panel A), 
whereas TFF3 protein expression was higher in the 
malignant tumor group (p<0.001) (Fig. 6, panel A). 
None of the tumor tissue subgroups, irrespective of 
malignancy, exhibited TFF2 protein expression (Fig. 7, 
panel B). Comparing the results between the sub-
groups defi ned according to the St. Gallen consensus, 
Lum A and Lum B tumor subgroups had the highest 
TFF1 protein expression (p<0.001) (Fig. 5, TFF1; Fig. 
6, panel B). TFF3 protein expression was highest in 
Lum B tumor subgroup (p<0.001) (Fig. 5, TFF3; Fig. 
6, panel B). Th e Her2 positive and triple negative 
 tumor subgroups had the lowest expression of both 
TFF1 and TFF3 proteins.
Discussion
In the present study, we examined the expression of 
all three TFF genes and TFF proteins in breast tumor 
tissue and compared them according to tumor malig-
nancy, diff erentiation grade, marker of cell prolifera-
tion (Ki67), and tendency to produce metastases in 
axillary lymph nodes. Expression of TFF genes was 
measured by qRT-PCR from total RNA isolated from 
tissue samples which had heterogeneous cell popula-
tion; to make sure that the vast amount of measured 
mRNA was from tumor tissue, protein products of 
Fig. 3. Distribution of TFF1 and TFF3 mRNA expression depending on histologic tumor grade diff erentiation: good 
(I), moderate (II) and poor (III) (panel A) and depending on the expression of proliferation marker Ki67 (%): low, 
moderate and high (panel B) within the malignant group of breast tumors. Th e test group comprised of 91 surgically 
removed malignant human breast tumors. Relative mRNA expression was measured by qRT-PCR; all measured genes 
were normalized to expression of Actin beta (ACTB) gene. Data are presented as median and interquartile range 
limits, horizontal bars represent the median, boxes indicate the range of the third and second quartiles, and whiskers 
represent extreme values of all data. Expression of both TFF1 and TFF3 mRNA was highest in the moderately 
diff erentiated (II) tumor subgroup (Kruskal Wallis test, p=0.008 and p=0.001, respectively) and in tumor subgroup 
with moderately high expression of Ki-67 (Kruskal Wallis test, p=0.19 and p=0.35, respectively); *p<0.05 was 
considered signifi cant.
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those genes were located by immunohistochemistry. 
Correlations between TFF within the tumor sub-
groups, and correlations of TFF with Ki67 and tumor 
diff erentiation grade were also examined.
TFF1
Many in vitro and in vivo studies of TFF1 gene 
and TFF1 protein have been performed in the past, 
however, scientists have not yet agreed about the role 
of TFF1 protein in tumor tissue, and whether its ac-
tion is pro-oncogenic or protective.
Th is study showed that TFF1 levels were higher in 
the benign group (fi broadenomas) compared to malig-
nant tumors. When TFF1 levels were compared be-
tween malignant tumor subgroups defi ned by the St. 
Gallen consensus, we found the highest TFF1 expres-
sion in Lum A and Lum B groups, both hormone re-
ceptor-positive tumors, which have a higher survival 
rate than hormone receptor-negative tumors37. In the 
subgroups according to the lymph node status, TFF1 
levels were higher in tumors without metastases in 
lymph nodes, also characterized by higher survival 
rate38. Our fi ndings are in line with the results from 
several previous studies indicating a high level of 
TFF1 gene expression in breast tumors as a biomarker 
of good prognosis, in spite of the fact that diff erent 
molecular methods and diff erent tumor classifi cations 
and models were used18,19. Th e study by Buache et al. 
demonstrated that TFF1 knock-out mice had a higher 
incidence and larger mammary cancers than wild-type 
mice, and in vitro experiment, performed in the same 
study, on estrogen receptor-positive and estrogen re-
ceptor-negative cell lines showed that TFF1 protein 
did not have oncogenic qualities18. Similarly, the study 
by Corte et al. showed that high cytosolic levels of 
TFF1 were associated with better clinical outcome 
and prolonged overall survival19. Even though the ex-
pression of TFF1 mRNA in our study was highest in 

Fig. 4. Correlation between TFF1 mRNA expression and 
expression of proliferation marker Ki67 (%) within the 
malignant tumor group (panel A), TFF3 mRNA 
expression and expression of Ki67 (%) within the 
malignant tumor group (panel B) and correlation 
between TFF3 mRNA expression and expression of Ki67 
(%) in the hormone receptor-positive (HR+) and in the 
hormone receptor-negative (HR-) malignant tumor 
subgroup (panel C). Mild negative correlation was 
observed between TFF1 and Ki67 and between TFF3 
and Ki67 within the malignant tumor group (Spearman 
rank correlation; p=0.028; ρ=-0.248 and p=0.011; ρ=-
0.285, respectively) and strong negative correlation 
between TFF3 and Ki67 within HR-tumor subgroup 
(Spearman rank correlation; p=0.03; ρ=-0.629); *p<0.05 
was considered signifi cant.
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tumors with moderately high Ki67 expression, the 
lowest values were measured in the tumor subgroup 
with high expression of Ki67. Results of TFF1 protein 
expression refl ected our fi ndings on the TFF1 gene ex-
pression analysis. Additionally, analysis of the correla-
tion between TFF1 gene and Ki67 showed that the 
expression of TFF1 decreased as Ki67 increased. Such 
fi ndings support the thesis that the higher expression 
of TFF1 means better prognosis for breast tumor pa-
tients, as it is known that the malignancy of a tumor 
increases as Ki67 increases39.
TFF2
Our results showed a very low level of TFF2 mRNA 
expression in benign breast tumor samples and almost 
no expression in malignant breast tumors. Consistently, 
immunohistochemical analysis did not reveal TFF2 
protein expression in a single sample. Our results are in 
accordance with the results of several previous studies 
that detected TFF2 gene expression in breast tumor cell 
lines, but not in human tissue22,23,40. Th e observed diff er-
ence between in vivo and in vitro experiments could be 
due to the greater number of parameters infl uencing 
regulation, expression and role of TFF2 gene and pro-
tein in in vivo conditions. Based on our fi ndings, TFF2 
gene and TFF2 protein have very poor potential as bio-
markers for breast tumor assessment.
TFF3
In this study, TFF3 was expressed in all tumor 
samples, but the highest expression was found in ma-
lignant tumors, unlike TFF1, which was highly ex-
pressed in benign tumors (fi broadenomas). Th e high-
est level of TFF3 expression among the malignant tu-
mor subgroups (defi ned according to St. Gallen con-
sensus) was in Lum B group, which is a hormone 
receptor-positive tumor subgroup. Additionally, the 
highest level of TFF3 expression was detected in grade 
I and grade II tumors, which conforms to the studies 
by Ahmed et al. and May and Westley, who found that 
TFF3 expression was higher in grade I tumors and in 
tumors with estrogen and progesterone receptor ex-
pression26,43. When the expression was compared 
among the subgroups with diff erent levels of Ki67 ex-
pression, the highest TFF3 expression was observed in 
the tumor subgroup with moderately high Ki67 ex-
pression. Th e TFF3 mRNA levels were higher in tu-
Fig. 5. Expression of TFF1 and TFF3 proteins in breast 
tumors. Th e test group comprised of 60 malignant human 
breast tumors and 15 benign (fi broadenomas) human 
breast tumors, surgically removed. Tumor tissues were 
collected intraoperatively, formalin-fi xed, paraffi  n-
embedded, and analyzed by immunohistochemistry. Th e 
immunohistochemical signal is visible in the cytoplasm of 
tumor cells. Representative examples of immunoreaction 
with gastric mucosa as positive control for TFF1 and colon 
mucosa for TFF3 (PC), fi broadenoma (F), Luminal A 
(LA), Luminal B (LB), Her2 positive (H) and triple 
negative tumors (TN) are shown. Scale bar, 60 μm.
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mors without metastases in lymph nodes than in tu-
mors that had spread into local or distant lymph nodes. 
Th ese results are in contrast to the fi ndings of the 
studies by Ahmed et al. and Pandey et al.26,29. Th e study 
by Ahmed et al., based on multivariate binary logistic 
regression analysis of several clinicopathologic features 
and molecular biomarkers, concluded that the higher 
expression of TFF3 protein could be a metastatic tu-
mor dissemination predictor26. Similarly, Pandey et al. 
conclude, based on TFF protein analysis in breast tu-
mors, that the TFF3 protein expression is signifi cantly 
associated with lymph node metastasis and stimulates 
cellular invasion, and is therefore a metastatic tumor 
dissemination predictor29. Strong positive correlation 
between TFF1 and TFF3, especially in tumors with a 
lower degree of malignancy, are consistent with the 
fi ndings that TFF1 and TFF3 have the same control-
ling mechanisms, such as estrogen responsiveness41,42. 
Our fi ndings of negative correlation between TFF3 
and Ki67 and positive correlation between TFF3 and 
TFF1 in hormone receptor-negative tumors suggested 
that the patients diagnosed with hormone receptor-
negative tumors with high levels of TFF3 expression 
could also benefi t from endocrine therapy because it is 
known that both TFF1 and TFF3 genes are regulated 
by estrogen41,42. Th is is further supported in the study 
by May and Westley, showing that TFF3 expression is 
an independent predictive biomarker of both estrogen 
response and degree of response43. Consistently to pre-
vious fi ndings, we demonstrated that the expression of 
TFF3 protein corresponded to the TFF3 mRNA ex-
pression.
Fig. 6. Distribution of TFF1 and TFF3 protein expression in benign (B) and malignant (M) breast tumors (panel A) 
and malignant tumor subgroups according to St. Gallen consensus (panel B). Th e test group comprised of 60 malignant 
human breast tumors and 15 benign (fi broadenomas) human breast tumors, surgically removed. Protein expression was 
assessed by immunohistochemistry and histomorphological analysis was performed using the modifi ed Quick Score 
method. Data are presented as median and interquartile range limits, horizontal bars represent the median, boxes 
indicate the range of the third and second quartiles, and whiskers represent extreme values of all data. Expression of 
TFF1 was signifi cantly higher in benign tumors (Mann Whitney U test, p<0.001), while the expression of TFF3 was 
signifi cantly higher in malignant tumors (Mann Whitney U test, p=0.001). According to the St. Gallen consensus 
subgroups, signifi cantly highest TFF1 expression was in Luminal A and Luminal B tumor subgroups (Kruskal Wallis 
test, p<0.001) and signifi cantly highest TFF3 expression was in Luminal B tumor subgroup (Kruskal Wallis test, 
p=0.001); *p<0.05 was considered signifi cant.
Maja Tolušić Levak et al. Diff erential expression of TFFs in breast tumors
Acta Clin Croat, Vol. 57, No. 2, 2018 275
In this study, we demonstrated the presence of 
TFF1 and TFF3 mRNA and their corresponding pro-
tein products in the investigated breast tumors with 
variable expression levels among diff erent tumor sub-
groups, while the TFF2 mRNA and TFF2 protein 
levels were low or undetectable. Our results suggest 
that TFF1 and TFF3, unlike TFF2, may have a role in 
breast tumor pathogenesis and could be used in the 
assessment of tumor malignancy only in particular 
breast tumor subgroups. Increased expression of TFF1 
could be used as a potential biomarker indicating a 
good prognosis, while TFF3 could be helpful in tumor 
status assessment; however, additional in vivo studies 
are needed to reach an agreement on the exact clinical 
impact of TFF molecules and their activity in breast 
tumor tissues.
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IZRAŽAJ TFF GENA I PROTEINA U TUMORIMA DOJKE
M. Tolušić Levak, M. Mihalj, I. Koprivčić, I. Lovrić, S. Novak, N. Bijelić, 
M. Baus-Lončar, T. Belovari, K. Kralik i B. Pauzar
Cilj ovoga istraživanja bio je utvrditi razlike u izražaju gena i proteina TFF1, TFF2 i TFF3 u različitim vrstama tumora 
dojke te ispitati korelacije između gena TFF i vrsta tumora te gena TFF i kliničko-patoloških karakteristika tumora. U stu-
diju su bile uključene 122 ispitanice kojima je kirurški odstranjen tumor dojke. Uzorci su obrađeni metodom qRT-PCR i 
metodom imunohistokemije. Geni i proteini TFF1 i TFF3 bili su izraženi u tumorima dojke, dok izražaj gena i proteina 
TFF2 nije otkriven u tumorskom tkivu. TFF1 je bio izraženiji kod dobroćudnih tumora, dok je TFF3 bio izraženiji kod 
zloćudnih tumora. TFF1 i TFF3 su bili izraženiji u hormonski ovisnim tumorima, tumorima bez metastaza u limfnim čvo-
rovima, tumorima s umjereno visokim izražajem Ki67 i umjereno diferenciranim tumorima. Jaka pozitivna korelacija uočena 
je između gena TFF1 i TFF3, a oba su negativno korelirala s faktorom Ki67 i stupnjem diferenciranosti tumora. Dobiveni 
rezultati pokazuju kako bi TFF1 i TFF3 mogli imati ulogu u patogenezi tumora dojke te bi se potencijalno mogli rabiti za 
određivanje tumorskog statusa i procjenu malignosti tumora.
Ključne riječi: tumorski proteini; dojka, tumori; imunohistokemija; lančana reakcija polimerazom; limfni čvorovi; Ki-67 anti-
gen; biomarkeri
